Product Description
In 2020, the South Korean orthobiologics market size was valued at $141.6 million, with over 200,000 bone grafting procedures performed every year. The market size is expected to increase at a compound annual growth rate (CAGR) of 3.6% to reach $181.5 million in 2026.
Throughout this medical market research, we analyzed 16 orthobiologics companies across South Korea and used our comprehensive methodology to understand the market sizes, unit sales, company market shares, and to create accurate forecasts.
While this MedSuite report contains all of the South Korean Orthopedic Biomaterials market data and analysis, each of the market segments is also available as stand-alone MedCore reports. This allows you to get access to only the market research that you need.
DATA TYPES INCLUDED
- Unit Sales, Average Selling Prices, Market Value & Growth Trends
- Forecasts Until 2026, and Historical Data to 2016
- Market Drivers & Limiters for Each Orthopedic Biomaterials Device market
- Competitive Analysis with Market Shares for Each Segment
- Recent Mergers & Acquisitions
- Orthopedic Biomaterials Procedure Volumes
- Disease Overviews and Demographic Information
- Company Profiles, Product Portfolios and SWOT for Top Competitors
- Related Press Releases from Top Competitors
Market Value and Industry Trends
A lack of product differentiation across similar injection cycle products has led to commoditization, which has stifled innovation and the further development of new products. Similar to Japan, the prices of HA viscosupplementation products in South Korea have drastically decreased since their introduction and are among the lowest in the world.
Surgical procedures that require the use of orthopedic biomaterials are generally associated with diseases and indications that become more prevalent in the population with an increase in age, such as osteoarthritis of the spine and knee. By 2020, approximately 15% of South Koreans were aged 65 and over; this proportion is projected to grow steadily over the forecast period, as further cohorts of baby boomers turn 65.
The bone graft substitute market in South Korea is primarily dominated by allografts and DBM allografts. A major driver to their usage is that they are both easily accessible, as they are distributed by several companies and bone banks.
Competitive Analysis
By 2020, the leading competitor in the South Korean orthopedic biomaterials market was Cellumed, which was attributed to its leading position in the orthopedic bone graft substitute market. The company held the second-leading position in the allograft and DBM allograft markets.
JunYoung Medical was the second-leading competitor, which was attributed to its second-leading position in the orthopedic bone graft substitute market. The company held the leading position in the allograft market and the third-leading position in the DBM allograft market. JunYoung Medical does not manufacture its own products, but instead distributes allograft and DBM allograft products for LifeNet Health.
Other notable competitors included, but were not limited to, Shin Poong, HansBiomed, LG Chem, and DongKook. The presence of local companies in South Korea is strong, and only a few international companies have been able to secure notable share in the orthopedic bone graft substitute market.
Segments Covered
Click on each title to view more detailed market segmentation.
- Procedure Volumes for Orthopedic Biomaterials Devices – MedPro – The complete procedural analysis for each segment of the South Korean Orthopedic Biomaterials market.
- Orthopedic Bone Graft Substitute Market – MedCore – This market is segmented by Material Type, including Allograft, Demineralized Bone Matrix Allograft, and Synthetic. Each of these material types are segmented by Indication, including Spine, Trauma, Large Joint Reconstruction, Foot Reconstruction, Craniomaxillofacial, and Oncology.
- Hyaluronic Acid Viscosupplementation Market – MedCore – This market is categorized by Treatment Type, including Single-Injection, Three-Injection and Five-Injection.
Detailed Market Segmentation
DON’T SEE THE SEGMENT OR DATA YOU NEED?
Feel free to contact us or send a request by pressing one of the buttons below.
FREE Sample Report
TABLE OF CONTENTS I
LIST OF FIGURES VIII
LIST OF CHARTS XV
EXECUTIVE SUMMARY 1
SOUTH KOREAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 1
COMPETITIVE ANALYSIS 3
MARKET TRENDS 5
MARKET DEVELOPMENTS 6
PROCEDURE NUMBERS 7
MARKETS INCLUDED 8
KEY REPORT UPDATES 10
VERSION HISTORY 10
RESEARCH METHODOLOGY 11
Step 1: Project Initiation & Team Selection 11
Step 2: Prepare Data Systems and Perform Secondary Research 14
Step 3: Preparation for Interviews & Questionnaire Design 16
Step 4: Performing Primary Research 17
Step 5: Research Analysis: Establishing Baseline Estimates 19
Step 6: Market Forecast and Analysis 20
Step 7: Identify Strategic Opportunities 22
Step 8: Final Review and Market Release 23
Step 9: Customer Feedback and Market Monitoring 24
PRODUCT ASSESSMENT 25
2.1 INTRODUCTION 25
2.2 PRODUCT PORTFOLIOS 25
2.2.1 Bone Graft Substitutes 26
2.2.2 Growth Factors 32
2.2.2.1 Other Products 35
2.2.3 Hyaluronic Acid Viscosupplementation (HAV) 37
2.3 REGULATORY ISSUES AND RECALLS 40
2.3.1 Bone Graft Substitutes 40
2.3.1.1 Allografts 40
2.3.1.1.1 MTF 40
2.3.1.2 DBM 40
2.3.1.2.1 AlloSource 40
2.3.1.2.2 SeaSpine 41
2.3.1.2.3 RTI Surgical 41
2.3.1.3 Synthetics 41
2.3.1.3.1 Abyrx 41
2.3.1.3.2 Zimmer Biomet 42
2.3.2 Growth Factors 42
2.3.2.1.1 Medtronic 42
2.3.3 Hyaluronic Acid Viscosupplementation 43
2.3.3.1 Three-injection 43
2.3.3.1.1 Ferring Pharmaceuticals 43
2.4 CLINICAL TRIALS 44
2.4.1 Bone Graft Substitutes 44
2.4.1.1 Allografts 44
2.4.1.1.1 Providence Medical Technology 44
2.4.1.1.2 The University of Texas Health Science 44
2.4.1.1.3 University of Winchester 45
2.4.1.2 BDM 45
2.4.1.2.1 K2M 45
2.4.1.2.2 Zimmer Biomet 46
2.4.1.3 Synthetics 46
2.4.1.3.1 Baxter 46
2.4.1.3.2 Bonesupport 47
2.4.1.3.3 DePuy Synthes 47
2.4.1.3.4 NuVasive 49
2.4.1.3.5 RTI surgical 49
2.4.1.3.6 Sunstar GUIDOR 50
2.4.1.4 Other materials and comparison 51
2.4.1.4.1 Seoul National University Hospital. 51
2.4.1.4.2 Sewon Cellontech 51
2.4.1.4.3 SurgaColl Technologies Limited 52
2.4.1.4.4 University of Colorado 52
2.4.1.4.5 University of Padova 53
2.4.2 Growth Factors 53
2.4.2.1.1 Bioventus 53
2.4.2.1.2 Cerapedics 54
2.4.2.1.3 CGBio 54
2.4.2.1.4 Isto 55
2.4.2.1.5 Medtronic 55
2.4.2.1.6 NuVasive 57
2.4.2.1.7 Wright 57
2.4.2.1.8 Others 58
2.4.3 Hyaluronic Acid Viscosupplementation 59
2.4.3.1.1 Anika Therapeutics 59
2.4.3.1.2 Bioventus 60
2.4.3.1.3 Cairo University 61
2.4.3.1.4 Ferring Pharmaceuticals 61
2.4.3.1.5 Federal University of Minas Gerais 62
2.4.3.1.6 Fidia Pharma USA Inc. 62
2.4.3.1.7 Istituto Ortopedico Rizzoli 63
2.4.3.1.8 University Hospital 63
2.4.3.1.9 Universidade Nova de Lisboa 64
SOUTH KOREAN ORTHOPEDIC BIOMATERIALS MARKET OVERVIEW 65
3.1 INTRODUCTION 65
3.1.1 Bone Graft Substitutes 65
3.1.2 Growth Factors 65
3.1.3 Hyaluronic Acid (HA) Viscosupplementation 66
3.2 CURRENCY EXCHANGE RATE 67
3.3 MARKET OVERVIEW AND TREND ANALYSIS 68
3.4 DRIVERS AND LIMITERS 75
3.4.1 Market Drivers 75
3.4.2 Market Limiters 75
3.5 COMPETITIVE MARKET SHARE ANALYSIS 77
3.6 MERGERS AND ACQUISITIONS 82
3.7 COMPANY PROFILES 84
3.7.1 Anika Therapeutics 84
3.7.2 Bioventus 85
3.7.3 DePuy Synthes 86
3.7.4 Ferring Pharmaceuticals 87
3.7.5 Fidia Pharmaceuticals 88
3.7.6 Genzyme (Sanofi Group) 89
3.7.7 Harvest Technologies (Terumo BCT) 90
3.7.8 Integra LifeSciences 91
3.7.9 Medtronic 92
3.7.10 Musculoskeletal Transplant Foundation (MTF) 94
3.7.11 NuVasive 95
3.7.12 Orthofix 96
3.7.13 RTI Surgical 97
3.7.14 Stryker 98
3.7.15 Vericel Corporation (formerly Aastrom Bioscience) 99
3.7.16 Zimmer Biomet 100
3.8 SWOT ANALYSIS 102
3.8.1 Anika Therapeutics 102
3.8.2 Bioventus 104
3.8.3 DePuy Synthes 106
3.8.4 Ferring Pharmaceuticals 107
3.8.5 Fidia Pharmaceuticals 108
3.8.7 Harvest Technologies (Terumo BCT) 110
3.8.8 Integra LifeSciences 111
3.8.9 Medtronic 112
3.8.10 Musculoskeletal Transplant Foundation (MTF) 113
3.8.11 NuVasive 114
3.8.12 Orthofix 115
3.8.14 Stryker 117
3.8.15 Vericel Corporation (formerly Aastrom Bioscience) 118
3.8.16 Zimmer Biomet 119
PROCEDURE NUMBERS 121
4.1 INTRODUCTION 121
4.2 PROCEDURES 122
4.2.1 Orthopedic Biomaterial Procedures by Segment 122
4.2.2 Orthopedic Bone Grafting Procedures 124
4.2.2.1 Units per Procedure by Indication 124
4.2.2.2 Orthopedic Bone Grafting Procedures by Material 125
4.2.2.2.1 Autograft Procedures by Indication 127
4.2.2.2.2 Allograft Procedures by Indication 130
4.2.2.2.3 DBM Procedures by Indication 133
4.2.2.2.4 Synthetic Procedures by Indication 136
4.2.2.3 Orthopedic Bone Grafting Procedures by Indication 139
4.2.3 Hyaluronic Acid Viscosupplementation Procedures 142
4.2.3.1 Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle 142
ORTHOPEDIC BONE GRAFT SUBSTITUTE MARKET 144
5.1 INTRODUCTION 144
5.2 MARKET OVERVIEW 145
5.2.1 Orthopedic Bone Graft Substitute Market by Material 145
5.2.2 Orthopedic Bone Graft Substitute Market by Indication 150
5.3 MARKET ANALYSIS AND FORECAST 156
5.3.1 Total Orthopedic Bone Graft Substitute Market 156
5.3.2 Orthopedic Bone Graft Substitute Market by Material 158
5.3.2.1 Allograft Bone Graft Substitute Market 158
5.3.2.1.1 Allograft Bone Graft Substitute Market by Indication 161
5.3.2.2 Demineralized Bone Matrix Allograft Bone Graft Substitute Market 175
5.3.2.2.1 Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication 178
5.3.2.3 Synthetic Bone Graft Substitute Market 192
5.3.2.3.1 Synthetic Bone Graft Substitute Market by Indication 195
5.3.3 Orthopedic Bone Graft Substitute Market by Indication 209
5.3.3.1 Spine Bone Graft Substitute Market 209
5.3.3.2 Cervical Spine Bone Graft Substitute Market 212
5.3.3.3 Thoracolumbar Spine Bone Graft Substitute Market 214
5.3.3.4 Trauma Bone Graft Substitute Market 216
5.3.3.5 Non-Union Trauma Bone Graft Substitute Market 219
5.3.3.6 Fresh Fracture Trauma Bone Graft Substitute Market 221
5.3.3.7 Large Joint Reconstruction Bone Graft Substitute Market 223
5.3.3.8 Hip Reconstruction Bone Graft Substitute Market 226
5.3.3.9 Knee Reconstruction Bone Graft Substitute Market 228
5.3.3.10 Foot Reconstruction Bone Graft Substitute Market 230
5.3.3.11 Craniomaxillofacial Bone Graft Substitute Market 233
5.3.3.12 Oncology Bone Graft Substitute Market 236
5.4 DRIVERS AND LIMITERS 239
5.4.1 Market Drivers 239
5.4.2 Market Limiters 239
5.5 COMPETITIVE MARKET SHARE ANALYSIS 241
HYALURONIC ACID VISCOSUPPLEMENTATION MARKET 245
6.1 INTRODUCTION 245
6.1.1 Benefits of Viscosupplementation 246
6.1.2 Synovial Fluid 246
6.2 MARKET OVERVIEW 247
6.3 MARKET ANALYSIS AND FORECAST 253
6.3.1 Total Hyaluronic Acid Viscosupplementation Market 253
6.3.2 Single-Injection Hyaluronic Acid Viscosupplementation Market 256
6.3.3 Three-Injection Hyaluronic Acid Viscosupplementation Market 259
6.3.4 Five-Injection Hyaluronic Acid Viscosupplementation Market 262
6.4 DRIVERS AND LIMITERS 265
6.4.1 Market Drivers 265
6.4.2 Market Limiters 265
6.5 COMPETITIVE MARKET SHARE ANALYSIS 267
APPENDIX: ORTHOPEDIC GROWTH FACTOR MARKET 271
7.1 INTRODUCTION 271
7.1.1 BMP-2 (Cellumed, CG Bio) 272
ABBREVIATIONS 273
The
Orthopedic Biomaterials Market Report Suite | South Korea | 2020-2026 | MedSuite includes analysis on the following companies currently active in this market:
- Cellumed
- CG Bio
- DePuy Synthes
- Dong Kwang
- DongKook
- Hanmi
- HansBiomed
- JunYoung Medical
|
- LG Chem
- Medtronic
- Sanofi
- SeaSpine
- Shin Poong
- Unimed
- Wright Medical
- Zimmer Biomet
|
LIST OF CHARTS
Chart 1 1: Orthopedic Biomaterials Market by Segment, South Korea, 2016 – 2026 2
Chart 1 2: Orthopedic Biomaterials Market Overview, South Korea, 2019 & 2026 2
Chart 3 1: Orthopedic Biomaterials Market by Segment, South Korea, 2016 – 2026 70
Chart 3 2: Orthopedic Biomaterials Market Breakdown, South Korea, 2019 71
Chart 3 3: Orthopedic Biomaterials Market Breakdown, South Korea, 2026 72
Chart 3 4: Growth Rates by Segment, Orthopedic Biomaterials Market, South Korea, 2017 – 2026 74
Chart 3 5: Leading Competitors, Orthopedic Biomaterials Market, South Korea, 2019 81
Chart 4 1: Orthopedic Biomaterials Market by Segment, South Korea, 2016 – 2026 123
Chart 4 2: Orthopedic Bone Grafting Procedures by Material, South Korea, 2016 – 2026 126
Chart 4 3: Autograft Procedures by Indication, South Korea, 2016 – 2026 129
Chart 4 4: Allograft Procedures by Indication, South Korea, 2016 – 2026 132
Chart 4 5: DBM Procedures by Indication, South Korea, 2016 – 2026 135
Chart 4 6: Synthetic Procedures by Indication, South Korea, 2016 – 2026 138
Chart 4 7: Orthopedic Bone Grafting Procedures by Indication, South Korea, 2016 – 2026 141
Chart 4 8: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, South Korea, 2016 – 2026 143
Chart 5 1: Orthopedic Bone Graft Substitute Market by Material, South Korea, 2016 – 2026 147
Chart 5 2: Orthopedic Bone Graft Substitute Market Breakdown by Material, South Korea, 2019 148
Chart 5 3: Orthopedic Bone Graft Substitute Market Breakdown by Material, South Korea, 2026 149
Chart 5 4: Orthopedic Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 153
Chart 5 5: Orthopedic Bone Graft Substitute Market Breakdown by Indication, South Korea, 2019 154
Chart 5 6: Orthopedic Bone Graft Substitute Market Breakdown by Indication, South Korea, 2026 155
Chart 5 7: Total Orthopedic Bone Graft Substitute Market, South Korea, 2016 – 2026 157
Chart 5 8: Allograft Bone Graft Substitute Market, South Korea, 2016 – 2026 160
Chart 5 9: Allograft Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 162
Chart 5 10: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, South Korea, 2016 – 2026 177
Chart 5 11: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 179
Chart 5 12: Synthetic Bone Graft Substitute Market, South Korea, 2016 – 2026 194
Chart 5 13: Synthetic Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 196
Chart 5 14: Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 211
Chart 5 15: Cervical Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 213
Chart 5 16: Thoracolumbar Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 215
Chart 5 17: Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 218
Chart 5 18: Non-Union Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 220
Chart 5 19: Fresh Fracture Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 222
Chart 5 20: Large Joint Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 225
Chart 5 21: Hip Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 227
Chart 5 22: Knee Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 229
Chart 5 23: Foot Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 232
Chart 5 24: Craniomaxillofacial Bone Graft Substitute Market, South Korea, 2016 – 2026 235
Chart 5 25: Oncology Bone Graft Substitute Market, South Korea, 2016 – 2026 238
Chart 5 26: Leading Competitors, Orthopedic Bone Graft Substitute Market, South Korea, 2019 244
Chart 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, South Korea, 2016 – 2026 250
Chart 6 2: Hyaluronic Acid Viscosupplementation Market Breakdown, South Korea, 2019 251
Chart 6 3: Hyaluronic Acid Viscosupplementation Market Breakdown, South Korea, 2026 252
Chart 6 4: Total Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 255
Chart 6 5: Single-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 258
Chart 6 6: Three-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 261
Chart 6 7: Five-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 264
Chart 6 8: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, South Korea, 2019 270
LIST OF FIGURES
Figure 1 1: Orthopedic Biomaterials Market Share Ranking by Segment, South Korea, 2019 3
Figure 1 2: Companies Researched in this Report 4
Figure 1 3: Factors Impacting the Orthopedic Biomaterials Market by Segment, South Korea 5
Figure 1 4: Recent Events in the Orthopedic Biomaterials Market, South Korea, 2017 – 2019 6
Figure 1 5: Orthopedic Biomaterials Procedures Covered, South Korea 7
Figure 1 6: Orthopedic Biomaterials Markets Covered (1 of 2) 8
Figure 1 7: Orthopedic Biomaterials Markets Covered (2 of 2) 9
Figure 1 8: Key Report Updates 10
Figure 1 9: Version History 10
Figure 2 1: Bone Graft Substitutes Products by Company (1 of 4) 28
Figure 2 2: Bone Graft Substitutes Products by Company (2 of 4) 29
Figure 2 3: Bone Graft Substitutes Products by Company (3 of 4) 30
Figure 2 4: Bone Graft Substitutes Products by Company (4 of 4) 31
Figure 2 5: Growth Factor Products by Company 36
Figure 2 6: Hyaluronic Acid Viscosupplementation by Products by Company 39
Figure 2 7: Class 2 Device Recall Musculoskeletal Transplant Foundation Allofix Insertion Kit 40
Figure 2 8: Class 2 Device Recall AlloFuse DBM Putty 5cc 40
Figure 2 9: Class 2 Device Recall Accell Evo3c Demineralized Bone Matrix Putty 41
Figure 2 10: Class 2 Device Recall RTI Biologics BioSet IC RT Paste 2 cc 41
Figure 2 11: Class 2 Device Recall Hemostatic Bone Putty 41
Figure 2 12: Class 2 Device Recall Endobon Xenograft Granules 42
Figure 2 13: Class 2 Device Recall Endobon Xenograft Granules 42
Figure 2 14: Class 2 Device Recall INFUSE Bone Graft X SMALL KIT 42
Figure 2 15: Class 3 Device Recall Euflexxa (1 sodium hyaluronate) 43
Figure 2 16: Evaluation of DTRAX Graft in Patients with Cervical Degenerative Disc Disease 44
Figure 2 17: Ridge Preservation Using FDBA and a Collagen Wound Dressing in Molar Sites. 44
Figure 2 18: Assessing Physical Activity Levels of Patients Following HTO. 45
Figure 2 19: Evaluation of Fusion Rate Using K2M VESUVIUS® Demineralized Fibers with K2M EVEREST® Spinal System 45
Figure 2 20: Evaluation of Zimmer Puros® Allograft vs. Creos™ Allograft for Alveolar Ridge Preservation 46
Figure 2 21: Synthetic Bone Graft Substitute vs. Autologous Spongiosa in Revision Anterior Cruciate Ligament Reconstruction 46
Figure 2 22: Cerament Treatment of Fracture Defects (CERTiFy) 47
Figure 2 23: Comparison of Bioactive Glass and Beta-Tricalcium Phosphate as Bone Graft Substitute (BAGvsTCP) 47
Figure 2 24: Evaluation of Fusion Rate of Anterior Cervical Discectomy and Fusion (ACDF) Using Cervios ChronOs™ and Bonion™ 48
Figure 2 25: AttraX® Putty vs. Autograft in XLIF® 49
Figure 2 26: Comparison of nanOss Bioactive with Autograft and Bone Marrow Aspirate to Autograft in the Posterolateral Spine 49
Figure 2 27: Assessment of nanOss Bioactive 3D in the Posterolateral Spine 50
Figure 2 28: Assessment of Ridge Preservation Using Moldable Beta-tricalcium Phosphate Bone Grafting System 50
Figure 2 29: Outcome Comparison of Allograft and Synthetic Bone Substitute in High Tibial Osteotomy 51
Figure 2 30: Efficacy and Safety of SurgiFill™ on Spinal Fusion 51
Figure 2 31: Assessment of HydroxyColl Bone Graft Substitute in High Tibial Osteotomy Wedge Grafting. (HColl_HTO) 52
Figure 2 32: Outcomes of the Evans Calcaneal Lengthening Based on Bone Grafting Material 52
Figure 2 33: Deproteinized Bovine Bone in Alveolar Bone Critical Size Defect (>2cm) Secondary to Cyst Removal 53
Figure 2 34: A Prospective Study of Instrumented, Posterolateral Lumbar Fusions (PLF) With OsteoAMP® 53
Figure 2 35: The Clinical Effect of i-FACTOR® Versus Allograft in Non-instrumented Posterolateral Spondylodesis Operation 54
Figure 2 36: Clinical Study of Injectable Ceramics Bone Graft Substitute Containing rhBMP-2 54
Figure 2 37: Prospective Study of Safety and Efficacy of InQu® Bone Graft Extender in Lumbar Interbody Fusion Surgery (Intebody) 55
Figure 2 38: A Study of INFUSE Bone Graft (BMP-2) in the Treatment of Tibial Pseudarthrosis in Neurofibromatosis Type 1 55
Figure 2 39: Clinical Study of INFUSE® Bone Graft Compared to Autogenous Bone Graft for Vertical Ridge Augmentation 56
Figure 2 40: Parallel Study Between BMP-2 and Autologous Bone Graft After Ilizarow Treatment 56
Figure 2 41: RCT of AttraX® Putty vs. Autograft in Instrumented Posterolateral Spinal Fusion (AxA) 57
Figure 2 42: Long-term Safety and Effectiveness of AUGMENT® Bone Graft Compared to Autologous Bone Graft 57
Figure 2 43: rhBMP-2 vs Autologous Bone Grafting for the Treatment of Non-union of the Docking Site in Tibial Bone Transport 58
Figure 2 44: Evaluation of Radiculitis Following Use of Bone Morphogenetic Protein-2 for Interbody Arthrodesis in Spinal Surgery 58
Figure 2 45: Study of Cingal™ for the Relief of Knee Osteoarthritis Compared to Triamcinolone Hexacetonide at 39 Weeks Follow-Up (Cingal17-02) 59
Figure 2 46: HyaloFAST Trial for Repair of Articular Cartilage in the Knee (FastTRACK) 59
Figure 2 47: Effectiveness of Two Hyaluronic Acids in Osteoarthritis of the Knee 60
Figure 2 48: The Effect of Topical Application of Hyaluronic Acid on Immediate Dental Implant 61
Figure 2 49: To Look at the Characteristics of Synovial Fluid and Cartilage Matrix in Osteoarthritic Knees After Hyaluronic Acid Injection 61
Figure 2 50: Use of Hyaluronic Acid as a Therapeutic Strategy for Bone Repair in Humans 62
Figure 2 51: Two Weekly Intra-articular Hyaluronan Knee Injections, Given One Week Apart, of HYMOVIS Combined With a Physical Exercise Program (PEP) Compared to PEP Alone, in a Relatively Young, Active Population of Subjects With Patellofemoral Osteoarthritis (PFOA) and/or Tibiofemoral Osteoarthritis (TFOA) 62
Figure 2 52: Comparative Assessment of Viscosupplementation With Polynucleotides and Hyaluronic Acid (PNHA1401) 63
Figure 2 53: Trial Comparing Botulin Toxin Versus Hyaluronic Acid by Intra-articular Injection (GOTOX) 63
Figure 2 54: Trial to Assess the Structural Effect and Long-term Symptomatic Relief of Intra-articular Injections of HA (ViscOA) 64
Figure 3 1: Currency Exchange Rate, 2019 67
Figure 3 2: Orthopedic Biomaterials Market by Segment, South Korea, 2016 – 2026 (US$M) 69
Figure 3 3: Orthopedic Biomaterials Market by Segment, South Korea, 2016 – 2026 (KR₩M) 69
Figure 3 4: Orthopedic Biomaterials Market Growth by Segment, South Korea, 2016 – 2026 73
Figure 3 5: Drivers and Limiters, Orthopedic Biomaterials Market, South Korea, 2019 76
Figure 3 6: Leading Competitors, Orthopedic Biomaterials Market, South Korea, 2019 80
Figure 3 7: SWOT Analysis, Anika Therapeutics (1 of 2) 102
Figure 3 8: SWOT Analysis, Anika Therapeutics (2 of 2) 103
Figure 3 9: SWOT Analysis, Bioventus (1 of 2) 104
Figure 3 10: SWOT Analysis, Bioventus (2 of 2) 105
Figure 3 11: SWOT Analysis, DePuy Synthes 106
Figure 3 12: SWOT Analysis, Ferring Pharmaceuticals 107
Figure 3 13: SWOT Analysis, Fidia Pharmaceuticals 108
Figure 3 14: SWOT Analysis, Genzyme (Sanofi) 109
Figure 3 15: SWOT Analysis, Harvest Technologies 110
Figure 3 16: SWOT Analysis, Integra LifeSciences 111
Figure 3 17: SWOT Analysis, Medtronic 112
Figure 3 18: SWOT Analysis, MTF 113
Figure 3 19: SWOT Analysis, NuVasive 114
Figure 3 20: SWOT Analysis, Orthofix 115
Figure 3 21: SWOT Analysis, RTI Surgical 116
Figure 3 22: SWOT Analysis, Stryker 117
Figure 3 23: SWOT Analysis, Vericel Corporation 118
Figure 3 24: SWOT Analysis, Zimmer Biomet (1 of 2) 119
Figure 3 25: SWOT Analysis, Zimmer Biomet (2 of 2) 120
Figure 4 1: Orthopedic Biomaterials Procedures by Segment, South Korea, 2016 – 2026 122
Figure 4 2: Units per Procedure by Indication, Bone Graft Substitute Market, South Korea, 2016– 2026 124
Figure 4 3: Orthopedic Bone Grafting Procedures by Material, South Korea, 2016 – 2026 125
Figure 4 4: Autograft Procedures by Indication, South Korea, 2016 – 2026 (1 of 2) 127
Figure 4 5: Autograft Procedures by Indication, South Korea, 2016 – 2026 (2 of 2) 128
Figure 4 6: Allograft Procedures by Indication, South Korea, 2016 – 2026 (1 of 2) 130
Figure 4 7: Allograft Procedures by Indication, South Korea, 2016 – 2026 (2 of 2) 131
Figure 4 8: DBM Procedures by Indication, South Korea, 2016 – 2026 (1 of 2) 133
Figure 4 9: DBM Procedures by Indication, South Korea, 2016 – 2026 (2 of 2) 134
Figure 4 10: Synthetic Procedures by Indication, South Korea, 2016 – 2026 (1 of 2) 136
Figure 4 11: Synthetic Procedures by Indication, South Korea, 2016 – 2026 (2 of 2) 137
Figure 4 12: Orthopedic Bone Grafting Procedures by Indication, South Korea, 2016 – 2026 (1 of 2) 139
Figure 4 13: Orthopedic Bone Grafting Procedures by Indication, South Korea, 2016 – 2026 (2 of 2) 140
Figure 4 14: Hyaluronic Acid Viscosupplementation Procedures by Injection Cycle, South Korea, 2016 – 2026 142
Figure 5 1: Orthopedic Bone Graft Substitute Market by Material, South Korea, 2016 – 2026 (US$M) 145
Figure 5 2: Orthopedic Bone Graft Substitute Market by Material, South Korea, 2016 – 2026 (KR₩M) 146
Figure 5 3: Orthopedic Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 (US$M) 151
Figure 5 4: Orthopedic Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 (KR₩M) 152
Figure 5 5: Total Orthopedic Bone Graft Substitute Market, South Korea, 2016 – 2026 156
Figure 5 6: Allograft Bone Graft Substitute Market, South Korea, 2016 – 2026 159
Figure 5 7: Allograft Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 (US$M) 161
Figure 5 8: Spine Allograft Market, South Korea, 2016 – 2026 163
Figure 5 9: Cervical Spine Allograft Market, South Korea, 2016 – 2026 164
Figure 5 10: Thoracolumbar Spine Allograft Market, South Korea, 2016 – 2026 165
Figure 5 11: Trauma Allograft Market, South Korea, 2016 – 2026 166
Figure 5 12: Non-Union Trauma Allograft Market, South Korea, 2016 – 2026 167
Figure 5 13: Fresh Fracture Trauma Allograft Market, South Korea, 2016 – 2026 168
Figure 5 14: Large Joint Reconstruction Allograft Market, South Korea, 2016 – 2026 169
Figure 5 15: Hip Reconstruction Allograft Market, South Korea, 2016 – 2026 170
Figure 5 16: Knee Reconstruction Allograft Market, South Korea, 2016 – 2026 171
Figure 5 17: Foot Reconstruction Allograft Market, South Korea, 2016 – 2026 172
Figure 5 18: Craniomaxillofacial Allograft Market, South Korea, 2016 – 2026 173
Figure 5 19: Oncology Allograft Market, South Korea, 2016 – 2026 174
Figure 5 20: Demineralized Bone Matrix Allograft Bone Graft Substitute Market, South Korea, 2016 – 2026 176
Figure 5 21: Demineralized Bone Matrix Allograft Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 (US$M) 178
Figure 5 22: Spine DBM Allograft Market, South Korea, 2016 – 2026 180
Figure 5 23: Cervical Spine DBM Allograft Market, South Korea, 2016 – 2026 181
Figure 5 24: Thoracolumbar Spine DBM Allograft Market, South Korea, 2016 – 2026 182
Figure 5 25: Trauma DBM Allograft Market, South Korea, 2016 – 2026 183
Figure 5 26: Non-Union Trauma DBM Allograft Market, South Korea, 2016 – 2026 184
Figure 5 27: Fresh Fracture Trauma DBM Allograft Market, South Korea, 2016 – 2026 185
Figure 5 28: Large Joint Reconstruction DBM Allograft Market, South Korea, 2016 – 2026 186
Figure 5 29: Hip Reconstruction DBM Allograft Market, South Korea, 2016 – 2026 187
Figure 5 30: Knee Reconstruction DBM Allograft Market, South Korea, 2016 – 2026 188
Figure 5 31: Foot Reconstruction DBM Allograft Market, South Korea, 2016 – 2026 189
Figure 5 32: Craniomaxillofacial DBM Allograft Market, South Korea, 2016 – 2026 190
Figure 5 33: Oncology DBM Allograft Market, South Korea, 2016 – 2026 191
Figure 5 34: Synthetic Bone Graft Substitute Market, South Korea, 2016 – 2026 193
Figure 5 35: Synthetic Bone Graft Substitute Market by Indication, South Korea, 2016 – 2026 (US$M) 195
Figure 5 36: Spine Synthetic Market, South Korea, 2016 – 2026 197
Figure 5 37: Cervical Spine Synthetic Market, South Korea, 2016 – 2026 198
Figure 5 38: Thoracolumbar Spine Synthetic Market, South Korea, 2016 – 2026 199
Figure 5 39: Trauma Synthetic Market, South Korea, 2016 – 2026 200
Figure 5 40: Non-Union Trauma Synthetic Market, South Korea, 2016 – 2026 201
Figure 5 41: Fresh Fracture Trauma Synthetic Market, South Korea, 2016 – 2026 202
Figure 5 42: Large Joint Reconstruction Synthetic Market, South Korea, 2016 – 2026 203
Figure 5 43: Hip Reconstruction Synthetic Market, South Korea, 2016 – 2026 204
Figure 5 44: Knee Reconstruction Synthetic Market, South Korea, 2016 – 2026 205
Figure 5 45: Foot Reconstruction Synthetic Market, South Korea, 2016 – 2026 206
Figure 5 46: Craniomaxillofacial Synthetic Market, South Korea, 2016 – 2026 207
Figure 5 47: Oncology Synthetic Market, South Korea, 2016 – 2026 208
Figure 5 48: Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 210
Figure 5 49: Cervical Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 212
Figure 5 50: Thoracolumbar Spine Bone Graft Substitute Market, South Korea, 2016 – 2026 214
Figure 5 51: Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 217
Figure 5 52: Non-Union Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 219
Figure 5 53: Fresh Fracture Trauma Bone Graft Substitute Market, South Korea, 2016 – 2026 221
Figure 5 54: Large Joint Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 224
Figure 5 55: Hip Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 226
Figure 5 56: Knee Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 228
Figure 5 57: Foot Reconstruction Bone Graft Substitute Market, South Korea, 2016 – 2026 231
Figure 5 58: Craniomaxillofacial Bone Graft Substitute Market, South Korea, 2016 – 2026 234
Figure 5 59: Oncology Bone Graft Substitute Market, South Korea, 2016 – 2026 237
Figure 5 60: Drivers and Limiters, Orthopedic Bone Graft Substitute Market, South Korea, 2019 240
Figure 5 61: Leading Competitors, Orthopedic Bone Graft Substitute Market, South Korea, 2019 243
Figure 6 1: Hyaluronic Acid Viscosupplementation Market by Segment, South Korea, 2016 – 2026 (US$M) 248
Figure 6 2: Hyaluronic Acid Viscosupplementation Market by Segment, South Korea, 2016 – 2026 (KR₩M) 249
Figure 6 3: Total Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 254
Figure 6 4: Single-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 257
Figure 6 5: Three-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 260
Figure 6 6: Five-Injection Hyaluronic Acid Viscosupplementation Market, South Korea, 2016 – 2026 263
Figure 6 7: Drivers and Limiters, Hyaluronic Acid Viscosupplementation Market, South Korea, 2019 266
Figure 6 8: Leading Competitors, Hyaluronic Acid Viscosupplementation Market, South Korea, 2019 269
iData’s 9-Step Research Methodology
Our reports follow an in-depth 9-step methodology which focuses on the following research systems:
- Original primary research that consists of the most up-to-date market data
- Strong foundation of quantitative and qualitative research
- Focused on the needs and strategic challenges of the industry participants
Step 1: Project Initiation & Team Selection During this preliminary investigation, all staff members involved in the industry discusses the topic in detail.
Step 2: Prepare Data Systems and Perform Secondary Research The first task of the research team is to prepare for the data collection process: Filing systems and relational databases are developed as needed.
Step 3: Preparation for Interviews & Questionnaire Design The core of all iData research reports is primary market research. Interviews with industry insiders represent the single most reliable way to obtain accurate, current data about market conditions, trends, threats and opportunities.
Step 4: Performing Primary Research At this stage, interviews are performed using contacts and information acquired in the secondary research phase.
Step 5: Research Analysis: Establishing Baseline Estimates Following the completion of the primary research phase, the collected information must be synthesized into an accurate view of the market status. The most important question is the current state of the market.
Step 6: Market Forecast and Analysis iData Research uses a proprietary method to combine statistical data and opinions of industry experts to forecast future market values.
Step 7: Identify Strategic Opportunities iData analysts identify in broad terms why some companies are gaining or losing share within a given market segment.
Step 8: Final Review and Market Release An integral part of the iData research methodology is a built-in philosophy of quality control and continuing improvement is integral to the iData philosophy.
Step 9: Customer Feedback and Market Monitoring iData philosophy of continuous improvement requires that reports and consulting projects be monitored after release for customer feedback and market accuracy.
Click Here to Read More About Our Methodology
